Evidence map›Paper›PMID 23451118›Full record

ArticlePloS one2013

Identification of a small molecule that selectively inhibits mouse PC2 over mouse PC1/3: a computational and experimental study.

Austin B Yongye, Mirella Vivoli, Iris Lindberg, Jon R Appel, Richard A Houghten, Karina Martinez-Mayorga

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 7 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Austin B YongyeTorrey Pines Institute for Molecular Studies, Port St Lucie, Florida, United States of America.
Mirella Vivoli
Iris Lindberg
Jon R Appel
Richard A Houghten
Karina Martinez-Mayorga
Torrey Pines Institute For Molecular Studies · USUniversity of Maryland, Baltimore · US

Funding

OPIOID PEPTIDE SYNTHESIZING ENZYMESR01DA005084 · NIDA · UNIVERSITY OF MARYLAND BALTIMORE · PI LINDBERG, IRIS · 1988 to 2014
$4.4M
Opioid Peptide Synthesizing EnzymesR56DA005084 · NIDA · UNIVERSITY OF MARYLAND BALTIMORE · PI LINDBERG, IRIS · 2016 to 2016
$174k
NIDA NIH HHS DA05084NIDA NIH HHS R01 DA005084NIDA NIH HHS R56 DA005084
6 · The paper itself

Abstract

The calcium-dependent serine endoproteases prohormone convertase 1/3 (PC1/3) and prohormone convertase 2 (PC2) play important roles in the homeostatic regulation of blood glucose levels, hence implicated in diabetes mellitus. Specifically, the absence of PC2 has been associated with chronic hypoglycemia. Since there is a reasonably good conservation of the catalytic domain between species translation of inhibitory effects is likely. In fact, similar results have been found using both mouse and human recombinant enzymes. Here, we employed computational structure-based approaches to screen 14,400 compounds from the Maybridge small molecule library towards mouse PC2. Our most remarkable finding was the identification of a potent and selective PC2 inhibitor. Kinetic data showed the compound to be an allosteric inhibitor. The compound identified is one of the few reported selective, small-molecule inhibitors of PC2. In addition, this new PC2 inhibitor is structurally different and of smaller size than those reported previously. This is advantageous for future studies where structural analogues can be built upon.

Indexed as

AnimalsDrug Evaluation, PreclinicalEnzyme InhibitorsMiceProprotein Convertase 1Proprotein Convertase 2Proprotein ConvertasesEnzyme InhibitorsProprotein Convertase 1Proprotein Convertase 2Proprotein Convertases

Identifiers

PMID23451118
PMCPMC3579927
OpenAlexW2002340364

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.